Nav: Home

A breakthrough for brain tumor drug development

February 05, 2019

A breakthrough for brain tumor drug development and personalised medicine published today in Nature Scientific Reports.

24,000 patients are diagnosed with brain tumors every year with the 5yr survival for high grade glioblastomas (GBM) only 5%, with median survival of 15 months. These poor statistics have remained static for 30 years due in part to a lack of human-relevant preclinical models for testing new drugs. In addition, high levels of inter-individual cellular and molecular heterogeneity of disease means each patient has unique treatment requirements, however the rapid pace of disease progression allows little time for individual assessments.

To address these challenges a multidisciplinary team of researchers in a public/private collaboration (MicroMatrices, Johns Hopkins University, the Mayo Clinic, and Perkin Elmer) have developed and evaluated a human induced pluripotent stem cell (IPSC) derived 3D organoid model for drug testing consisting of differentiated neurons and other non-neuronal brain cells (glial cells, astrocytes and oligodendrocytes) grown alongside patient-derived glioblastoma tumor cells. Accurate drug efficacy measurements were facilitated through the use of a microTMA-based high throughput histology platform (SpheroMatricesTM).

To investigate the potential of this platform, two chemotherapeutic agents were tested: temozolomide (TMZ), the current front line treatment option for glioblastoma, and an experimental therapy doxorubicin (DOX).

The study results indicated the system could predict a clinical response to TMZ and also demonstrated anti-tumor efficacy with DOX . Furthermore as the microTMA technology allows for multiplexing of different measurements, it was also observed that DOX acted via selective killing of tumour cells (apoptosis) with little or no effect on normal brain cells.

This system can be adapted for use with publicly available libraries of glioblastoma patient-derived cell lines, paving the way for the creation of a more efficient discovery platform for new therapies, ultimately offering a more personalized approach by matching patients to therapies that are more likely to work clinically. In previous screens, the patient-derived cells were grown in immune-compromised mice, a model which cannot capitulate the environment of human tumours. By contrast, the organoid model system more closely mirrors a human-relevant microenvironment. In addition, the microTMA technology, by making multiple parallel measurements of efficacy end-points, produces quantitative data supporting mechanistic insights and informative biomarkers with greater potential to translate to the clinic.

Simon Plummer CEO of MicroMatrices said 'this breakthrough study illustrates how human relevant 3D models can make an impact for drug development and personalised medicine'.
-end-


MicroMatrices

Related Glioblastoma Articles:

Spanish researchers find a new promising therapeutic target for glioblastoma
Glioblastoma is the most frequent and aggressive brain cancer due to its ability to escape the immune system.
Texas A&M CVM study finds new pathway for potential glioblastoma treatment
A team led by Texas A&M University's College of Veterinary Medicine & Biomedical Sciences' (CVM) researcher Dr.
New research published in cancer discovery identifies new drug target for glioblastoma
A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma.
Interregional differences in somatic genetic landscape diversify prognosis in glioblastoma
Interregional differences in somatic genetic landscape diversify prognosis in glioblastoma.
Two-pronged gene therapy for glioblastoma proves safe in phase 1 trial
A phase 1 clinical trial has demonstrated that a two-step gene therapy treatment was safe and effective in 31 patients with recurrent glioblastoma -- a stubborn form of brain cancer -- potentially overcoming a major hurdle that has hindered the use of systemically administered interleukin 12 (IL-12)-based regimens.
Single-cell sequencing reveals glioblastoma's shape-shifting nature
Glioblastoma, a cancer that arises in the brain's supporting glial cells, is one of the worst diagnoses a child can receive.
Adding MS drug to targeted cancer therapy may improve glioblastoma outcomes
The multiple sclerosis drug teriflunomide, paired with targeted cancer therapy, markedly shrinks patient-derived glioblastomas grown in mice by reaching stem cells at the tumor's root, according to a new UC San Diego School of Medicine study published in Science Translational Medicine.
Clinical trial identifies new breast cancer drug as a potential therapy for glioblastoma
Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma.
Study identifies new potential target in glioblastoma
Researchers are hopeful that new strategies could emerge for slowing the growth and recurrence of the most common primary brain cancer in adults, glioblastoma, based on the results of a study published today in Cancer Research.
Tumour treating fields in glioblastoma: Indication of a benefit
The additional application of the new treatment method prolongs survival, as a recent study shows.
More Glioblastoma News and Glioblastoma Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.